歌礼制药:进军减重大市场,自研GLP-1 药令人期待:公司致力于代谢性疾病的创新药物开发和商业化,公司成立于2013 年,由吴劲梓先生创办。于2018 年在香港证券交易所上市。公司的实控人为吴劲梓博士,是公司创始人、董事长、首席执行官。吴劲梓博士直接和间接持有公司59.39%的股份。歌礼制药管理层经验丰富,有跨国一线制药公司高管背景,具有丰富的研发管理经验和业内资源。公司核心管线为小分子GLP-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."